All In Biotech

Drug Trial Radar · NCT04358393

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

69

Planned (sponsor's estimate)

Start

Dec 4, 2020

Primary completion

Dec 30, 2024

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.

Conditions

  • AML
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • CMML
  • Myelodysplastic Syndromes
  • High-risk Myelodysplastic Syndrome
  • MDS

Interventions

  • APG-115Drug

    APG-115 given once daily on day 1-5 of every 28 day cycle

  • 5-azacitidineDrug

    5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated DoseTime frame: 28 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • Texas Oncology - Tyler

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Seattle Cancer Care Alliance

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.